(R)-2-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)propan-1-amine 2,2,2-trifluoroacetate
| Product Name |
(R)-2-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)propan-1-amine 2,2,2-trifluoroacetate
|
| Product Code |
DA-B169-21
|
| Chemical name |
(R)-2-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)propan-1-amine 2,2,2-trifluoroacetate
|
| Synonyms |
NA
|
| Impurity |
NA
|
| CAS Number |
94242-81-6
|
| Alternate CAS # |
NA
|
| Molecular form |
C16H27BF3NO4
|
| Appearance |
NA
|
| Melting Point |
NA
|
| Mol. Weight |
365.2
|
| Storage |
2-8°C Refrigerator
|
| Solubility |
NA
|
| Stability |
NA
|
| Category |
impurities,metabolites,pharmaceutical standards,intermediates,fine chemicals
|
| Boiling Point |
NA
|
| Applications |
[3as-[2(s*),3a,4b,6b,7a]]-Hexahydro-3a,5,5-trimethyl-alpha-(1-methylethyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine Trifluoroacetate is an impurity of Bortezomib, Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.
|
| Dangerous Goods Info |
NA
|
| References |
NA
|
| Extra Notes |
NA
|
| Documents (MSDS) |
No Data Available
|
| Keywords |
NA |
